CAMBRIDGE, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Idera Pharmaceuticals,
Inc. (Amex: IDP) announced today that Sudhir Agrawal, D. Phil, Chief Executive
Officer and Chief Scientific Officer of Idera Pharmaceuticals, Inc. will
present an overview of the Company, its product pipeline and its technology to
investors at the BIO InvestorForum, taking place at The Palace Hotel in San
Francisco. The presentation will be made on Thursday, October 20, 2005 at
1:40 p.m. PT in the Telegraph Hill Room.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. is a biotechnology company focused on the
discovery, development, and commercialization of targeted immune therapies
based on modulation of Toll-like Receptors (TLRs). Idera has identified novel
chemical entities that modulate immune responses through interactions with
TLR9. The Company continues to identify new drug candidates specific to
various diseases, including cancer, infectious diseases and asthma/allergies,
based on the differentiated biological activities of its proprietary
compounds. The Company's website is located at http://www.iderapharma.com.
Idera Pharmaceuticals (Amex: IDP) is based in Cambridge, Massachusetts.
Idera's lead candidate is IMO2055, a TLR9 agonist currently in Phase 2
clinical testing for cancer. Idera is also collaborating with Novartis for
the discovery, development, and commercialization of IMO drug candidates
targeting asthma and allergies.
Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For
this purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking statements. There
are a number of important factors that could cause Idera's actual results to
differ materially from those indicated by such forward-looking statements,
including whether products based on Idera's technology will advance through
the clinical trial process on a timely basis or at all and receive approval
from the United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether, if such products receive approval, they will be
successfully distributed and marketed; whether Idera's cash resources will be
sufficient to fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors" in Idera's
Quarterly Report on Form 10-Q filed on August 9, 2005, which important factors
are incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements.
Contacts:
Idera Pharmaceuticals, Inc. MacDougall Biomedical Communications
617-679-5500 x5517 508-647-0209 x12
Robert G. Andersen Douglas MacDougall
E-mail: randersen@iderapharma.com E-mail:doug@macbiocom.com
SOURCE Idera Pharmaceuticals, Inc.
 back to top
Related links:
http://www.iderapharma.com
CONTACT:
Robert G. Andersen of Idera Pharmaceuticals,
Inc., +1-617-679- 5500 ext 5517, randersen@iderapharma.com; or
Douglas MacDougall of MacDougall Biomedical Communications,
+1-508-647-0209 ext 12, or doug@macbiocom.com
|
